Combination of Chemotherapy and Gefitinib as First-line Treatment
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The results of fastact2 show that chemotherapy plus erlotinib significantly prolonged PFS and
OS of patients with NSCLC. However, outcome of the combination therapy are similar to those
reported in several trials of single-agent EGFR TKIs. So which is the optimal first-line
treatment for patients who harbored a sensitive EGFR mutation? The investigators need a
head-to-head study to reply.